SLU-PP-332

Third-Party Tested

Independent lab verified

Batch-Specific CoA

Publicly accessible

YPB.243

Reference number

5mg

Lyophilized vial

Origin

SLU-PP-332 was developed by Thomas Bhatt and colleagues in Thomas Bhatt's laboratory at Saint Louis University (hence the SLU prefix). It was identified through a structure-activity relationship campaign targeting estrogen-related receptors (ERRs), a family of orphan nuclear receptors linked to mitochondrial function and energy metabolism.

Research Lineage

Kim et al. published the characterization in 2023, describing SLU-PP-332 as a pan-agonist of ERRalpha, ERRbeta, and ERRgamma with exercise-mimetic effects in mouse models. The compound was observed to increase fatigue resistance and shift muscle fiber type composition in sedentary mice. It represents a pharmacological approach to activating exercise-responsive transcriptional programs.

Mechanism of Action

SLU-PP-332 activates all three estrogen-related receptors (ERRalpha, ERRbeta, ERRgamma), which regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, and fatty acid oxidation. ERR activation has been observed to upregulate PGC-1alpha target genes and increase mitochondrial DNA content. In muscle tissue models, this shifts fiber type markers from glycolytic (Type IIb) toward oxidative (Type I/IIa).

Structural Notes

Small molecule (not a peptide). Synthetic ERR agonist. Molecular formula and weight are defined in patent literature.